Polymer Capital Management (HK) LTD
Position in SABS — SAB Biotherapeutics, Inc.
CIK 1970465
HONG KONG, K3
Position in SABS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,195,665
New position
Shares Held
306,581
first reported quarter
Ownership
0.337%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#31
of 86 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Polymer Capital Management (HK) LTD holds $79,733,655 across 15 Biotechnology names. SABS ranks #13 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
64,957 | $19,554,005 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
177,897 | $14,105,453 | |
| 3 | CYTK |
Cytokinetics Inc
|
138,255 | $11,777,943 | |
| 4 | ERAS |
Erasca, Inc.
|
478,020 | $8,757,326 | |
| 5 | LEGN |
Legend Biotech Corp
|
165,209 | $4,771,235 | |
| 6 | CRVS |
Corvus Pharmaceuticals, Inc.
|
263,662 | $3,939,110 | |
| 7 | SMMT |
Summit Therapeutics Inc.
|
224,853 | $3,276,108 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
36,800 | $2,999,568 |
All Filings in SABS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,195,665 | 306,581 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||